LivaNova PLC (NASDAQ:LIVN) Given Consensus Rating of "Buy" by Brokerages

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has received an average recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $59.29.

LIVN has been the subject of several research analyst reports. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a report on Tuesday, May 20th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Robert W. Baird boosted their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th.

LivaNova Stock Up 0.0%

NASDAQ LIVN traded up $0.02 during trading hours on Tuesday, reaching $43.19. 596,572 shares of the company's stock were exchanged, compared to its average volume of 655,499. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of 102.83 and a beta of 0.84. The company's 50-day moving average is $39.05 and its two-hundred day moving average is $44.28. LivaNova has a one year low of $32.48 and a one year high of $61.40.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. UMB Bank n.a. boosted its stake in shares of LivaNova by 340.5% during the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after buying an additional 647 shares during the last quarter. CWM LLC raised its holdings in LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after acquiring an additional 299 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock worth $58,000 after acquiring an additional 1,184 shares in the last quarter. Russell Investments Group Ltd. boosted its position in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Finally, Sterling Capital Management LLC grew its stake in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.